Hims & Hers Health says it will offer compounded GLP-1 drugs, despite FDA warningsMarket Watch • 05/20/24
Is Hims & Hers Health (HIMS) a Buy as Wall Street Analysts Look Optimistic?Zacks Investment Research • 05/20/24
Hims & Hers Announces Access to GLP-1 Injections, Passing Cost Savings Onto CustomersBusiness Wire • 05/20/24
Hims & Hers Welcomes Anja Manuel, Foreign Policy Expert, Domestic Regulations Advisor, and Former Diplomat to its Board of DirectorsBusiness Wire • 05/16/24
Earnings Estimates Rising for Hims & Hers Health (HIMS): Will It Gain?Zacks Investment Research • 05/15/24
Hims & Hers Health Shares Climb After News of Double-Digit Revenue Growth. Is It Too Late to Buy the Stock?The Motley Fool • 05/11/24
Hims & Hers Health (HIMS) Upgraded to Strong Buy: What Does It Mean for the Stock?Zacks Investment Research • 05/08/24
Hims & Hers Health, Inc. (HIMS) Q1 Earnings and Revenues Top EstimatesZacks Investment Research • 05/06/24
Hims & Hers shares rally as forecast bumped higher and more profitability said to be aheadMarket Watch • 05/06/24
Hims & Hers CEO walks back praise for anti-Israel protesters after stock dropsFox Business • 05/06/24